ArticleFrontiers in cell and developmental biology2025
Aquaporin 2 is differentially expressed in granulosa cells of various stages of human follicles and is regulated by luteinizing hormone.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Several aquaporins (AQPs) are involved in the influx of water to form follicular fluid, and AQP2 may play a crucial role in follicular growth. However, the specific roles of Aquaporin (AQP) 2 and AQP6 in granulosa cells (GCs) during follicular fluid (FF) formation, as well as their relationship with gonadotropins (Gn), remain unclear. Methods: Luteinized granulosa cells (LGCs) were isolated from follicles of different diameters. Western blot indicated that AQP2 protein levels in LGCs increased as follicles grew larger after luteinization. Immunohistochemistry of human ovarian sections showed that AQP2 levels decreased as follicles progressed from primordial to antral stages. Subsequently, isolated LGCs were treated with varying concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2); LH, but not FSH or E2, significantly elevated AQP2 expression. To dissect the underlying signaling pathways, LGCs were further cultured with LH, db-cAMP (a cAMP analog), or forskolin (an adenylate cyclase activator). H89 (a PKA inhibitor) or PD98059 (an ERK1/2 signaling inhibitor) was applied in the presence of LH to evaluate crosstalk between the Gn/cAMP and MAPK cascades. Results: AQP2 levels in LGCs increased with follicle enlargement after luteinization but decreased as follicles progressed from primordial to antral stages. LH, but not E2, significantly induced AQP2 expression in LGCs in a dose-dependent manner. Forskolin mimicked the stimulatory effect of LH on AQP2 expression. PD98059, but not H89, abolished LH-induced AQP2 up-regulation and inhibited ERK1/2 phosphorylation, indicating potential crosstalk between cAMP and MAPK signaling. Discussion: This study provides the first evidence for the mechanisms by which AQP2 influences follicular growth and FF formation, highlighting LH-driven, ERK1/2-dependent regulation of AQP2. These findings offer new insights into the ovarian microenvironment and identify potential therapeutic targets for follicle growth disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.